N-acetylcysteine ameliorates repetitive/stereotypic behavior due to its antioxidant properties without activation of the canonical Wnt pathway in a valproic acid-induced rat model of autism

Zhang,Yinghua; Cui,Weigang; Zhai,Qianqian; Zhang,Tianran; Wen,Xiaojun

doi:10.3892/mmr.2017.6787

N-acetylcysteine ameliorates repetitive/stereotypic behavior due to its antioxidant properties without activation of the canonical Wnt pathway in a valproic acid-induced rat model of autism

Authors:
- Yinghua Zhang
- Weigang Cui
- Qianqian Zhai
- Tianran Zhang
- Xiaojun Wen
View Affiliations

Affiliations: Henan Key Laboratory of Medical Tissue Regeneration, Department of Human Anatomy, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Endocrinology, The First Affiliated Hospital, Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Undergraduate Student of Basic Medicine School, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
Published online on: June 15, 2017 https://doi.org/10.3892/mmr.2017.6787
Pages: 2233-2240

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

N-acetylcysteine (NAC) is widely used as an antioxidant, and previous studies have suggested that it may have potential as an alternative therapeutic strategy for the treatment of patients with autism. However, the exact effects of NAC administration on the development of autism, as well as the molecular mechanisms underlying its actions, have yet to be fully elucidated. The present study aimed to investigate the effects of NAC on the oxidative status of rats in a valproic acid (VPA)‑induced model of autism, and to examine the involvement of the canonical Wnt signaling pathway in the actions of NAC. Rats exposed to VPA were monitored for behavioral changes, and oxidative stress indicators and key molecules of the canonical Wnt pathway were investigated using colorimetric and western blot analysis, respectively. The present results demonstrated that NAC ameliorated repetitive and stereotypic activity in autism model rats. Furthermore, NAC was revealed to relieve oxidative stress, as demonstrated by the increased glutathione and reduced malondialdehyde levels compared with VPA‑treated rats. However, NAC did not appear to affect the activity of the canonical Wnt signaling pathway. The present findings suggested that the beneficial effects of NAC in autism may be associated with its antioxidative properties, and may not be mediated by the canonical Wnt pathway. However, it may be hypothesized that the canonical Wnt pathway can be indirectly regulated by NAC through the activation of other signaling pathways or upstream factors. Taken together, the present study has contributed to the elucidation of the molecular mechanisms that underlie the actions of NAC in autism, suggesting its potential for the development of novel therapeutic strategies for the treatment of patients with autism.

View Figures

View References

1	Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D and Charman T: Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: The special needs and autism project (SNAP). Lancet. 368:210–215. 2006. View Article : Google Scholar : PubMed/NCBI
2	Levitt P and Campbell DB: The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest. 119:747–754. 2009. View Article : Google Scholar : PubMed/NCBI
3	Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN, Daniels J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, et al: Prevalence and characteristics of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ. 65:1–23. 2016. View Article : Google Scholar : PubMed/NCBI
4	Ghezzo A, Visconti P, Abruzzo PM, Bolotta A, Ferreri C, Gobbi G, Malisardi G, Manfredini S, Marini M, Nanetti L, et al: Oxidative stress and erythrocyte membrane alterations in children with autism: Correlation with clinical features. PLoS One. 8:e664182013. View Article : Google Scholar : PubMed/NCBI
5	Ghanizadeh A, Akhondzadeh S, Hormozi M, Makarem A, Abotorabi-Zarchi M and Firoozabadi A: Glutathione-related factors and oxidative stress in autism, a review. Curr Med Chem. 19:4000–4005. 2012. View Article : Google Scholar : PubMed/NCBI
6	Dean O, Giorlando F and Berk M: N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 36:78–86. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ghanizadeh A and Derakhshan N: N-acetylcysteine for treatment of autism, a case report. J Res Med Sci. 17:985–987. 2012.PubMed/NCBI
8	Paintlia MK, Paintlia AS, Barbosa E, Singh I and Singh AK: N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J Neurosci Res. 78:347–361. 2004. View Article : Google Scholar : PubMed/NCBI
9	Wang X, Svedin P, Nie C, Lapatto R, Zhu C, Gustavsson M, Sandberg M, Karlsson JO, Romero R, Hagberg H and Mallard C: N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury. Ann Neurol. 61:263–271. 2007. View Article : Google Scholar : PubMed/NCBI
10	Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA and Morley JE: The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 84:1173–1183. 2003. View Article : Google Scholar : PubMed/NCBI
11	Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Öz G, Cloyd JC and Tuite PJ: N-acetylcysteine boosts brain and blood glutathione in gaucher and parkinson diseases. Clin Neuropharmacol. 36:103–106. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, Frazier TW and Tirouvanziam R: A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 71:956–961. 2012. View Article : Google Scholar : PubMed/NCBI
13	Marler S, Sanders KB and Veenstra-VanderWeele J: N-acetylcysteine as treatment for self-injurious behavior in a child with autism. J Child Adolesc Psychopharmacol. 24:231–234. 2014. View Article : Google Scholar : PubMed/NCBI
14	Ghanizadeh A and Moghimi-Sarani E: A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 13:1962013. View Article : Google Scholar : PubMed/NCBI
15	Nikoo M, Radnia H, Farokhnia M, Mohammadi MR and Akhondzadeh S: N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: A randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 38:11–17. 2015. View Article : Google Scholar : PubMed/NCBI
16	Chen YW, Lin HC, Ng MC, Hsiao YH, Wang CC, Gean PW and Chen PS: Activation of mGluR2/3 underlies the effects of N-acetylcystein on amygdala-associated autism-like phenotypes in a valproate-induced rat model of autism. Front Behav Neurosci. 8:2192014. View Article : Google Scholar : PubMed/NCBI
17	Kimelman D and Xu W: Beta-catenin destruction complex: Insights and questions from a structural perspective. Oncogene. 25:7482–7491. 2006. View Article : Google Scholar : PubMed/NCBI
18	Sierra J, Yoshida T, Joazeiro CA and Jones KA: The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev. 20:586–600. 2006. View Article : Google Scholar : PubMed/NCBI
19	Toledo EM, Colombres M and Inestrosa NC: Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol. 86:281–296. 2008. View Article : Google Scholar : PubMed/NCBI
20	Zhuang B, Luo X, Rao H, Li Q, Shan N, Liu X and Qi H: Oxidative stress-induced C/EBPβ inhibits β-catenin signaling molecule involving in the pathology of preeclampsia. Placenta. 36:839–846. 2015. View Article : Google Scholar : PubMed/NCBI
21	Hsu YC, Lee PH, Lei CC, Ho C, Shih YH and Lin CL: Nitric oxide donors rescue diabetic nephropathy through oxidative-stress-and nitrosative-stress-mediated Wnt signaling pathways. J Diabetes Investig. 6:24–34. 2015. View Article : Google Scholar : PubMed/NCBI
22	Yoshida GJ and Saya H: Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun. 443:622–627. 2014. View Article : Google Scholar : PubMed/NCBI
23	Hormozdiari F, Penn O, Borenstein E and Eichler EE: The discovery of integrated gene networks for autism and related disorders. Genome Res. 25:142–154. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Yuan X, Wang Z and Li R: The canonical Wnt signaling pathway in autism. CNS Neurol Disord Drug Targets. 13:765–770. 2014. View Article : Google Scholar : PubMed/NCBI
25	Marui T, Funatogawa I, Koishi S, Yamamoto K, Matsumoto H, Hashimoto O, Jinde S, Nishida H, Sugiyama T, Kasai K, et al: Association between autism and variants in the wingless-type MMTV integration site family member 2 (WNT2) gene. Int J Neuropsychopharmacol. 13:443–449. 2010. View Article : Google Scholar : PubMed/NCBI
26	Schneider T, Turczak J and Przewłocki R: Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: Issues for a therapeutic approach in autism. Neuropsychopharmacology. 31:36–46. 2006.PubMed/NCBI
27	Silvestrin R Bristot, Bambini-Junior V, Galland F, Bobermim L Daniele, Quincozes-Santos A, Abib R Torres, Zanotto C, Batassini C, Brolese G, Gonçalves CA, et al: Animal model of autism induced by prenatal exposure to valproate: Altered glutamate metabolism in the hippocampus. Brain Res. 1495:52–60. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Sun Y, Wang F, Wang Z, Peng Y and Li R: Downregulating the canonical Wnt/β-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress. Neurochem Res. 37:1409–1419. 2012. View Article : Google Scholar : PubMed/NCBI
29	Slattery J Deepmala, Kumar N, Delhey L, Berk M, Dean O, Spielholz C and Frye R: Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 55:294–321. 2015. View Article : Google Scholar : PubMed/NCBI
30	Wink LK, Adams R, Wang Z, Klaunig JE, Plawecki MH, Posey DJ, McDougle CJ and Erickson CA: A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 7:262016. View Article : Google Scholar : PubMed/NCBI
31	Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004. View Article : Google Scholar : PubMed/NCBI
32	Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Melnyk S and James SJ: Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines. Transl Psychiatry. 4:e3772014. View Article : Google Scholar : PubMed/NCBI
33	Gvozdjáková A, Kucharská J, Ostatníková D, Babinská K, Nakládal D and Crane FL: Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longev. 2014:7989572014. View Article : Google Scholar : PubMed/NCBI
34	Gu F, Chauhan V and Chauhan A: Glutathione redox imbalance in brain disorders. Curr Opin Clin Nutr Metab Care. 18:89–95. 2015. View Article : Google Scholar : PubMed/NCBI
35	Raymond LJ, Deth RC and Ralston NV: Potential role of selenoenzymes and antioxidant metabolism in relation to autism etiology and pathology. Autism Res Treat. 2014:1649382014.PubMed/NCBI
36	James SJ, Rose S, Melnyk S, Jernigan S, Blossom S, Pavliv O and Gaylor DW: Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 23:2374–2383. 2009. View Article : Google Scholar : PubMed/NCBI
37	Green JL, Heard KJ, Reynolds KM and Albert D: Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and meta-analysis. West J Emerg Med. 14:218–226. 2013. View Article : Google Scholar : PubMed/NCBI
38	Quintavalle C, Donnarumma E, Fiore D, Briguori C and Condorelli G: Therapeutic strategies to prevent contrast-induced acute kidney injury. Curr Opin Cardiol. 28:676–682. 2013. View Article : Google Scholar : PubMed/NCBI
39	Liu XH, Xu CY and Fan GH: Efficacy of N-acetylcysteine in preventing atrial fibrillation after cardiac surgery: A meta-analysis of published randomized controlled trials. BMC Cardiovasc Disord. 14:522014. View Article : Google Scholar : PubMed/NCBI
40	Shahripour R Bavarsad, Harrigan MR and Alexandrov AV: N-acetylcysteine (NAC) in neurological disorders: Mechanisms of action and therapeutic opportunities. Brain Behav. 4:108–122. 2014. View Article : Google Scholar : PubMed/NCBI
41	Berk M, Malhi GS, Gray LJ and Dean OM: The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 34:167–177. 2013. View Article : Google Scholar : PubMed/NCBI
42	Baker MS, Feigan J and Lowther DA: Chondrocyte antioxidant defences: The roles of catalase and glutathione peroxidase in protection against H2O2 dependent inhibition of proteoglycan biosynthesis. J Rheumatol. 15:670–677. 1988.PubMed/NCBI
43	Zhou T, Zhou KK, Lee K, Gao G, Lyons TJ, Kowluru R and Ma JX: The role of lipid peroxidation products and oxidative stress in activation of the canonical wingless-type MMTV integration site (WNT) pathway in a rat model of diabetic retinopathy. Diabetologia. 54:459–468. 2011. View Article : Google Scholar : PubMed/NCBI
44	Gong SP, Lee EJ, Lee ST, Kim H, Lee SH, Han HJ and Lim JM: Improved establishment of autologous stem cells derived from preantral follicle culture and oocyte parthenogenesis. Stem Cells Dev. 17:695–712. 2008. View Article : Google Scholar : PubMed/NCBI
45	Zhang Y, Yang C, Yuan G, Wang Z, Cui W and Li R: Sulindac attenuates valproic acid-induced oxidative stress levels in primary cultured cortical neurons and ameliorates repetitive/stereotypic-like movement disorders in Wistar rats prenatally exposed to valproic acid. Int J Mol Med. 35:263–270. 2015.PubMed/NCBI
46	Wang Z, Xu L, Zhu X, Cui W, Sun Y, Nishijo H, Peng Y and Li R: Demethylation of specific Wnt/β-catenin pathway genes and its upregulation in rat brain induced by prenatal valproate exposure. Anat Rec (Hoboken). 293:1947–1953. 2010. View Article : Google Scholar : PubMed/NCBI
47	Strakovsky RS and Pan YX: A decrease in DKK1, a WNT inhibitor, contributes to placental lipid accumulation in an obesity-prone rat model. Biol Reprod. 86:812012. View Article : Google Scholar : PubMed/NCBI
48	Chen JR, Lazarenko OP, Shankar K, Blackburn ML, Badger TM and Ronis MJ: A role for ethanol-induced oxidative stress in controlling lineage commitment of mesenchymal stromal cells through inhibition of Wnt/beta-catenin signaling. J Bone Miner Res. 25:1117–1127. 2010. View Article : Google Scholar : PubMed/NCBI
49	McGrew LL, Takemaru K, Bates R and Moon RT: Direct regulation of the Xenopus engrailed-2 promoter by the Wnt signaling pathway, and a molecular screen for Wnt-responsive genes, confirm a role for Wnt signaling during neural patterning in Xenopus. Mech Dev. 87:21–32. 1999. View Article : Google Scholar : PubMed/NCBI
50	Bilodeau JF, Wang M, Chung FL and Castonguay A: Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice. Free Radic Biol Med. 18:47–54. 1995. View Article : Google Scholar : PubMed/NCBI
51	Dairam A, Müller AC and Daya S: Non-steroidal anti-inflammatory agents, tolmetin and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats. Life Sci. 80:1431–1438. 2007. View Article : Google Scholar : PubMed/NCBI
52	Sur A, Kesaraju S, Prentice H, Ayyanathan K, Baronas-Lowell D, Zhu D, Hinton DR, Blanks J and Weissbach H: Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α. Proc Natl Acad Sci USA. 111:16754–16759. 2014. View Article : Google Scholar : PubMed/NCBI